Since the first acquired immunodeficiency syndrome cases were reported in 1981, more than 1.5 million people have been diagnosed with Human Immunodeficiency Virus-1 in Europe, including more than 136,000 new HIV cases in 2013. Recent epidemiological data estimate an incidence of 5-10 newly diagnosed HIV infections per 100,000 population per year in Europe and an average prevalence of infection of 5.7 cases per 100,000 population. In the absence of an effective curative strategy for HIV, optimization of prevention policies and clinical management of HIV positive patients is fundamental to reduce the impact of the HIV pandemic on public health. Clinical trials represent an essential tool for translating research findings into routine clinical practice. Careful evaluation and planning of clinical trials are therefore mandatory in order to provide relevant information to clinicians. The HEFFICON Project was conceived to investigate and pinpoint methodological issues and critical points that need to be addressed in future clinical studies to increase the translation of experimental results to the real life environment.
HEFFICON : HIV Effectiveness Italian Conference / A. Antinori, M. Andreoni, C. Perno, A. Lazzarin, A. Ammassari, P. Bonfanti, S. Bonora, M. Borderi, M. Capobianchi, A. Castagna, M. Clementi, P. Cinque, A. d'Arminio Monforte, G. Di Perri, M. Galli, A. Gori, P. Maggi, C. Mastroianni, C. Mussini, E. Nicastri, M. Puoti, S. Rusconi, M. Santoro, G. Tambussi. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - 38:2(2015), pp. 149-184.
|Titolo:||HEFFICON : HIV Effectiveness Italian Conference|
|Parole Chiave:||AIDS; HAART; HIV; Integrase inhibitors; Anti-HIV Agents; Europe; HIV Infections; HIV-1; Humans|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||2015|
|Appare nelle tipologie:||01 - Articolo su periodico|